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Abstract 
The emergence of immunotherapy as a prominent modality to treat cancer is a crucial 
advancement in the fight against this devastating disease. Although DNA vaccines against cancer 
have not been effective in treating pre-existing tumors, this approach holds much promise 
particularly for the activation of immune responses to specific mutant antigens responsible for 
tumorigenesis. Recent studies demonstrated that Q209L point mutation in the GNAQ (and 
GNA11) is responsible for the development of more than 70% of uveal melanomas and pre-
malignant cutaneous blue nevus in humans. Based on the epitope prediction, we hypothesized 
that DNA vaccination with mutant GNAQ may result in presentation of the mutant GNAQ 
peptide by human and mouse MHC class I and activation of the mutation specific immune 
response. A DNA vaccine was developed containing a plasmid encoding VP22-mutant GNAQ-
PADRE fusion protein (pEF1-VP22-mtGNAQ-PADRE). To enhance vaccine efficacy, 
pBOOST2-mIRF7/3 plasmid encoding interferon regulatory factors 7/3 and chemokines (CCL20 
and CCL21) were used along with vaccination. Three separate experimental naïve mouse groups 
were vaccinated with variable vaccine compositions via intradermal in vivo electroporation. 
Assessment of the immune response induction by IFN ELISpot assay showed activation of the 
mutation specific immune response in all vaccinated groups. This analysis also demonstrated 
detrimental and stimulating effects of CCL20 and CCL21, respectively on the activation of 
mtGNAQ-specific immune response. Moreover, in all vaccinated groups we observed GNAQ-
specific activation of humoral immune responses. Collectively, our studies demonstrated that 
mutant GNAQ-specific immune response can be induced by the enhanced DNA vaccination. 
This suggests potential therapeutic utility of this approach for the treatment/prophylactics of 
GNAQ/GNA11 uveal melanoma.  
 
Introduction 
In the human body, pigment-producing cells (melanocytes) normally reside in the skin, 
eyes, ears, leptomeninges, oral and genital mucous membranes. Tumorigenic transformation of 
these cells leads to the development of a melanocytic malignancy also known as melanoma. 
Better understanding of the human immune system over the last 50 years along with the 
discovery of tumor-associated antigens (TAAs) in the 1980s (1) led to the development of the 
new field of modern biomedical science - tumor immunotherapy. Recently, multiple approaches 
aimed at the utilization of the immune system to fight cancer were developed. One of these 
approaches is DNA vaccination. The original idea of DNA vaccination emanated from the 
observations that intramuscular injection of plasmid DNA encoding influenza A virus protein 
resulted in the induction of specific humoral and cellular responses that protect against viral 
challenge (2). These findings have led to the development of simple and potentially powerful 
technology of DNA vaccination. Initial studies on DNA vaccination were carried out using an 
intramuscular route of vaccine administration. Later, DNA vaccination through the skin was 
suggested to be superior over the intramuscular route. DNA vaccination approach has several 
advantages: (i) multiple expression vectors coding for different proteins (e.g. antigen and co-
stimulatory molecules) can be concurrently delivered into skin; (ii) the use of cell-type-specific 
promoters can provide targeted expression of the antigen; (iii) protein expression from designed 
plasmids can be controlled by inducible promoters. Multiple studies on pre-clinical animal 
models of melanoma and other cancers have been conducted. Studies on canine model of 
aggressive and metastatic melanoma (stages II-IV) were very successful ((3, 4)). Several recent 
studies on tumor animal models demonstrated that DNA vaccination can be successful in 
eliciting tumor-specific immune responses and protective immunity against the tumors [(5, 6)]. 
However, up to date only a few human clinical trials on DNA vaccination were conducted. One 
of such study showed that DNA vaccination with a prostate-specific antigen encoding plasmid 
vector, given with GM-CSF and IL-2 is safe and in doses of up to 900 g, and that vaccination 
can induce cellular and humoral immune responses against the antigen (7). Yet, the effectiveness 
of these DNA vaccines in human clinical trials remains to be seen.  
Uveal melanoma is a cancer of the eye that can affect the iris, the ciliary body, or 
the choroid. This form of cancer leads to the development of tumors which arise from the 
melanocytes that reside within the uvea, giving color to the eye. Conventional treatments for this 
disease include surgery and radiotherapy. Other modalities of treatment include 
transpupillary thermotherapy, external beam proton therapy, and resection of the tumor. There 
are however, currently no uveal-melanoma-specific immunotherapy treatments available. Recent 
studies demonstrated that more than 70% of uveal melanomas and melanocytomas of the central 
nervous system are associated with the Q209L mutation in the GNAQ (and highly homologous 
GNA11) protein ((8, 9)).  
Our analysis of the protein structure using epitope prediction software (SYFPEITHI, 
http://www.syfpeithi.de) showed that GNAQ mutant peptide F R M V D V G G L  (mutant 
amino acid underlined) has a high probability to be loaded and presented by the mouse and 
human MHC class I. Therefore, we hypothesized that DNA vaccination with mutant GNAQ may 
result in the expression of the mutated antigen in the Dendritic Cells (DC), presentation of this 
mutant peptide, and activation of the mutation specific immune response.  
Results 
Vaccine design 
Based on previous findings ((10-12)), we suggested that DNA vaccine efficacy can be enhanced 
by inclusion of VP22 and PADRE epitopes into vaccine composition and expression of the 
interferon response factos7 and 3 (IRF7/3) along with the vaccine. This was achieved by 
generating an expression vector encoding mutant GNAQ fused in frame with VP22 cDNA and 
PADRE epitope (Fig 1). For the expression of the IRFs,  a pBOOST2-mIRF7/3 (Invivogen, San 
Diego, CA) was used (Fig 1). Based on the previous findings, administration of the CCL20 and 
CCL21 chemokines that recruit immature DC and T cells, respectively, was used (Fig 1)  
Fig. 1. Maps of the plasmids used in vaccination protocols.  
Fig. 2. Electroporation of plasmid DNA into mouse skin. 
(A) – BTX830 electroporator with tweezertroads electrodes and a mouse (for size 
reference). (B) – Photographic image of the GFP-electroporated skin 48 h after the 
procedure taken under zoom fluorescent microscopy. (C) – Direct fluorescent microscopy of 
the cross-section of the pMaxGFP-electroporated skin. On B and C – green – GFP 
fluorescence, on C – blue – DAPI nuclear staining. 
 
Analysis of antigen expression 
To provide efficient expression of the antigen in the skin, we used BTX830 in vivo DNA 
electroporation system (Fig. 2A). To test whether previously established conditions for the 
intradermal gene transfer provide expression of the transgene, in the first set of experiments we 
used an expression vector (pMaxGFP, Lonza) encoding green fluorescent protein as a reporter. 
Injection and electroporation of the pMaxGFP led to a significant expression of the GFP in the 
Fig.3. Analysis of antigen expression in mouse skin after 
electroporation. 
Lanes 1 and 3 - pEF1-VP22-mtGNAQ-PADRE 
electroporated skin; Lanes 2 and 4 – control skin. 
Genes-specific primers are indicated above the panels. 
Arrows to the left point to the position of the band 
corresponding to respective genes. 
skin as detected by fluorescent zoom microscopy (Fig. 2B). Expression of the GFP was observed 
throughout the epidermis and the dermis of the skin by direct fluorescent microscopy (Fig. 2C). 
To further assess the expression of the antigen, pEF1-VP22-mtGNAQ-PADRE vector 
was electroporated under similar conditions into mouse skin. Control mouse was electroporated 
with a mock plasmid containing no insert. Forty eight hours later, skin biopcies from vaccine and 
control electroporated skin were collected. Then, total RNA was isolated and used for the 
assessment of the antigen expression by one-step RT-PCR. For the PCR, primers specific to 
VP22 and GNAQ were used. Same amount (100 ng) of total RNA was used for this assessment. 
Based on agarose gel electrophoresis, amplification of the RNA corresponding to VP22 was 
detected only in the vaccine electroporated skin. At the same time, enhanced expression of the 
GNAQ was detected in this sample (Fig. 3).  
Collectively, these analyses demonstrated that in vivo intradermal electroporation is a 
suitable method of expression of the plasmid-derived proteins in the skin and that  mutant 
GNAQ antigen can be successfully expressed in the skin.  
Intradermal vaccination 
In these experiments, three groups of C57BL6 mice (3 animals per group) were used. Each 
mouse was intradermally electroporated with vaccines four separate times, with 4-5 days in-
between each vaccination. Group 1 mice received an initial dose of chemokine CCL20 alone to 
recruit Antigen-Presenting Cells. This was followed by the administration of the full vaccine four 
days later. Group 2 mice received doses of pEF1-VP22-mutGNAQ-PADRE along with 
pBOOST2-IRF7/3. Group 3 mice received doses of the full vaccine: pEF1-VP22-mutGNAQ-
PADRE along with pBOOST2-IRF7/3 and CCL21.  
Analysis of immune responses 
Fig. 4. Elispot analysis. 
Average number of spots per group is presented. Individual 
groups and controls are indicated below the graph. 
To assess activation of the cellular immune response, two weeks after last immunization, two 
mice from each group were 
euthanized for analysis of 
immune response. Splenocytes 
were isolated and used in the 
IFN ELISpot assay. For this 
assay, effector cells 
(splemocytes from control and 
differentially treated mice) 
were co-cultured with 
mitomycin C treated target 
cells. As target cells, mouse 
melanocytes genetically 
engineered to express mutant GNAQ were used. To determine, whether immune response was to 
GNAQ or it was specific to its mutant form as a mutation control parental mouse melanocytes 
(melan-a cells) were used. Target and effector cells were co-cultured for 48 on the ELISPot 
plated pre-treated with IFN-capturing antibodies (eBioscience). Upon IFN detection, 
individual spots were enumerated. As expected, in all negative control wells, we did not detect 
any significant number of spots whereas naïve cells treated with PHA show a significant number 
of spots. On the contrary, splenocytes from the first treatment group showed elevated number of 
spots when incubated with wild type and particularly cells expressing mutant GNAQ (Fig. 4). 
Similar pattern was observed in all examined groups. I seem to be important to mention that 
there have been only minor variations between individual animals within the groups. 
 To investigate whether vaccinated animals developed any antibody response againsed 
mutant or wild type GNAQ, serum was obtained from each animal and tested for the presence of 
the antibodies by ELISA assay. To establish this assay, we used rabbit polyclonal antibodies 
against GNAQ (Santa Cruz Biotchnology) coated onto ELISA plated. As a sourse of the antigen, 
we used cell lysated expressing either wild type or mutant GNAQ. Mouse serum was used as a 
detection antibody and anti-mouse IgG-specific HRP-labeled antibodies were used for detection 
of the immune-complexes.  
Fig. 5. Sandwich ELISA assay against wild type and mutant GNAQ. 
Data is presented as a relative reactivity with cell lysates (OD at 450nm). Average readings 
were used for each groups. Background (reactivity of serum isolated from the control mice) 
was subtracted. 
 
As shown on figure 5, the overall trend of reactivity was similar with the highest reactivity 
detected in group 1 and the lowest in group 3. Group 3 mice showed mediun range of GNAQ-
reactive antibodies as compared to Group 1 and 2. Very surprisingly, reactivity of the antibodies 
from group 3 mice were elevated at a higher dilution when tested against mutant GNAQ.  
 
Discussion 
 Previously, different methods were used to deliver DNA vaccines. Most common is the 
intramuscular injection of the DNA. Alternatively, several studies tested particle bombardment 
methods (gene gun) for DNA vaccination. Here we demonstrated that in vivo electroporation, 
although not yet optimized, provides an effective means to express antigens in the skin. Taking 
into account the fact that particle bombardment is not yet approved for the human use and 
electroporation already have been tested in several clinical investigations, our data suggest that 
DNA vaccination through the skin using in vivo electroporation is a suitable approach. 
Having established electroporation, we differentially vaccinated mice in the absence of 
presence of leukocyte-recruiting chemokines. Based on our in vitro analyses of immune 
response, pre-treatment of the skin with CCL20 does not significantly enhance immunogenicity 
of the DNA vaccine at least cell mediated immunity against mutant GNAQ. However, this 
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recruitment of the responding leukocytes prior to the vaccination may potentially result in the 
effective acquisition of the expressed antigen and its preferential presentation via MHC class II 
mechanism and activation of humoral immune response. In part this could be explained by the 
elevated presence of the macrophages that could respond to the chemokine and/or to the tissue 
injury by the electroporation. As macrophages can serve as antigen presenting cells, it is possible 
that these cells take part in the activation of the humoral immune responses.  
At the same time, our analyses of humoral and cellular immune responses demonstrated 
that DNA vaccination alone preferentially induces cellular immune response to the antigen, as 
seen in the data obtained in Group 2. However, the highest cellular mutant GNAQ-specific 
response was observed when CCL21 cDNA was included in the vaccination protocol, as detected 
in Group 3. Interestingly, this mice treated with DNA vaccine and CCL21 also showed elevated 
level of the mutant GNAQ-reactive antibodies, suggesting that this vaccine composition 
enhances immunogenicity of the DNA vaccine and activates both cellular and humoral arms of 
the immune system. 
Collectively, our studies demonstrated that mutation-specific immune response can be 
induced using DNA vaccination and that differential immune responses can be induce by varying 
DNA vaccine compositions. This studies formed the platform for the future investigations and 
development of the cancer-specific DNA vaccines. 
 
Materials and Methods: 
DNA preparation. Maxi-preps of Ampicillin resistant bacteria containing pEF1-VP22-PADRE 
(VPG) DNA were prepared. DNA was isolated and purified 24hours later. Electrophoresis was 
conducted to confirm presence of pEF1-VP22-PADRE (VPG) DNA. Maxi-preps of Ampicillin 
resistant (mutGNAQ) and Zeocin resistant (pBOOST) bacteria were prepared. DNA was isolated 
from each prep and Gel electrophoresis was conducted to confirm the presence of mtGNAQ and 
pBOOST plasmid DNA. 
In vivo electroporation. Intradermal electroporation of the Green Fluorescent Protein (GFP) 
encoding plasmid was carried out in a C57BL6 mouse. This analysis confirmed efficient in vivo 
electroporation-based expression of the antigen in the skin. 
Analysis of antigen expression. RT-PCR – based analysis was conducted of the antigen 
expression in mouse skin 48 h after electroporation of the pEF1-VP22-mtGNAQ-PADRE 
plasmid. 
Vaccination. Three groups of C57BL6 mice with three mice in each group were used for 
intradermal electroporation. Group 1 mice received an initial dose of Chemokine (C-C motif) 
ligand 20 alone to recruit Antigen-presenting Cells. This was followed by the full vaccine four 
days later. Group 2 mice received doses of pEF1-VP22-mutGNAQ-PADRE along with 
pBOOST2-IRF7/3. Group 3 mice received doses of the full vaccine: pEF1-VP22-mutGNAQ-
PADRE along with pBOOST2-IRF7/3 and Chemokine (C-C motif) ligand 21.  
Each group was intradermally electroporated with their respective vaccines four separate times, 
with 4-5 days in-between each vaccination. 
Splenocytes isolation. Upon completion of their respective vaccination series (2 week after last 
immunization), two mice from each group were euthanized. Their blood was drawn and their 
spleens were harvested. Splenocytes were isolated from each of the harvested spleens according 
to the standard protocol. 
ELISpot assay. IFN ELISpot assay was then conducted using the isolated splenocytes to 
measure the immune response of each mouse. This was done by first irradiating the mutGNAQ 
target cells. Each well of the ELISpot plate was then primed with Antibodies and incubated at 
4
o
C overnight. Coating antibody was then aspirated and two washes were conducted using 200ul 
sterile ELISpot Coating Buffer. 200ul of 10%FBS RPMI1640 was then added and incubated for 
1 hour at RT for blocking. The plate was then aspirated. Mouse splenocytes were then added to 
each well. The prepared GNAQ cells (prepared via irradiation) were added to each well, except 
for control wells (which only received media). The plate was left to incubate for 48 hours in a 
37
o
C humidified incubator. Detection of IFN-gamma then followed. This was done by washing 
the plate three times with ELISpot wash buffer. 100ul of dilute biotinylated detection antibody 
solution was added and incubated at RT for 2 hours. The plate was then washed 4 times with 
ELISpot wash buffer. 100ul of dilute Avidin-HRP reagent was added to each well and incubated 
at RT for 45 minutes. The plate was then washed and 100ul of AEC Substrate solution was 
added and left to develop at RT for 30 minutes. The substrate reaction was stopped by washing 
the wells three times with 200ul distilled water. The plate was left to air dry and the spots were 
using an automated ELISpot plate reader.  
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